Garcia-Velasco Juan A, Mulayim Naciye, Kayisli Umit A, Arici Aydin
IVI-Madrid, Madrid, Spain.
Fertil Steril. 2002 Oct;78(4):855-9. doi: 10.1016/s0015-0282(02)03320-4.
To evaluate soluble Fas ligand concentrations in serum and peritoneal fluid from women with endometriosis and from fertile controls without endometriosis, and to study levels of soluble Fas ligand in conditioned media of cultured endometrial stromal cells.
Prospective, experimental trial.
Two academic IVF centers.
PATIENT(S): Twenty-nine fertile women without endometriosis and 57 infertile women with endometriosis (32 with stage I or II disease and 25 with stage III or IV disease).
MAIN OUTCOME MEASURE(S): Enzyme-linked immunosorbent assay was used to measure soluble Fas ligand concentrations in paired samples of serum and peritoneal fluid from women with and without endometriosis. Concentrations were also measured in conditioned media of cultured endometrial stromal cells at basal conditions and after stimulation with interleukin-8 (0.001-10 ng/mL) and tumor necrosis factor-alpha (1-10 ng/mL).
RESULT(S): Compared with fertile controls and women with early-stage of endometriosis, women with moderate to severe endometriosis had elevated serum (87.2 +/- 6.4, 88.2 +/- 6.9, and 162.3 +/- 7.8 pg/mL, respectively) and peritoneal fluid (81.0 +/- 6.0, 80.5 +/- 6.8, and 166.2 +/- 10.3 pg/mL, respectively) concentrations of soluble Fas ligand. Serum levels of soluble Fas ligand positively correlated with levels in peritoneal fluid. Comparison of patients in the same menstrual cycle in each group revealed that increased levels of soluble Fas ligand in patients with advanced endometriosis were not attributable to the difference in cycle phases. Soluble Fas ligand was not detected in conditioned media of endometrial stromal cells under baseline conditions or after stimulation.
CONCLUSION(S): Serum and peritoneal fluid of women with moderate to severe endometriosis contain elevated concentrations of soluble Fas ligand compared to women with minimal or mild endometriosis and women without endometriosis. These findings suggest a role for apoptotic dysregulation in the pathophysiology of endometriosis.
评估子宫内膜异位症患者及无子宫内膜异位症的正常生育对照者血清和腹水中可溶性Fas配体的浓度，并研究培养的子宫内膜基质细胞条件培养基中可溶性Fas配体的水平。
前瞻性实验研究。
两个学术性体外受精中心。
29名无子宫内膜异位症的正常生育女性和57名患有子宫内膜异位症的不孕女性（32例为I期或II期疾病，25例为III期或IV期疾病）。
采用酶联免疫吸附测定法测量有或无子宫内膜异位症女性血清和腹水配对样本中可溶性Fas配体的浓度。同时测量培养的子宫内膜基质细胞在基础条件下以及用白细胞介素-8（0.001 - 10 ng/mL）和肿瘤坏死因子-α（1 - 10 ng/mL）刺激后的条件培养基中可溶性Fas配体的浓度。
与正常生育对照者及早期子宫内膜异位症患者相比，中重度子宫内膜异位症患者血清（分别为87.2±6.4、88.2±6.9和162.3±7.8 pg/mL）和腹水（分别为81.0±6.0、80.5±6.8和166.2±10.3 pg/mL）中可溶性Fas配体浓度升高。血清中可溶性Fas配体水平与腹水中水平呈正相关。对每组处于相同月经周期的患者进行比较发现，晚期子宫内膜异位症患者可溶性Fas配体水平升高并非归因于月经周期阶段的差异。在基础条件下或刺激后，子宫内膜基质细胞的条件培养基中未检测到可溶性Fas配体。
与轻度或无子宫内膜异位症的女性相比，中重度子宫内膜异位症患者的血清和腹水中可溶性Fas配体浓度升高。这些发现提示凋亡调节异常在子宫内膜异位症病理生理过程中起作用。
